PXRB Stock Overview
PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
PixarBio Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
PXRB | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | -0.06% | 2.1% |
1Y | n/a | 9.8% | 30.4% |
Return vs Industry: Insufficient data to determine how PXRB performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PXRB performed against the US Market.
Price Volatility
PXRB volatility | |
---|---|
PXRB Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PXRB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PXRB's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Frank Reynolds | https://www.pixarbio.com |
PixarBio Corporation, a specialty pharmaceutical/biotechnology company, focuses on the pre-clinical and clinical development of neurological drug delivery systems for post-operative pain. The company researches and develops delivery systems for drugs, devices, or biologics to treat pain, epilepsy, epilepsy, Parkinson’s disease, and spinal cord injury. Its principal product platform is NeuroRelease for the therapeutic release of non-opiate drugs for post-operative, acute, and chronic pain in pre-clinical models.
PixarBio Corporation Fundamentals Summary
PXRB fundamental statistics | |
---|---|
Market cap | US$81.00 |
Earnings (TTM) | -US$12.19m |
Revenue (TTM) | US$7.50k |
0.0x
P/S Ratio0.0x
P/E RatioIs PXRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PXRB income statement (TTM) | |
---|---|
Revenue | US$7.50k |
Cost of Revenue | US$0 |
Gross Profit | US$7.50k |
Other Expenses | US$12.20m |
Earnings | -US$12.19m |
Last Reported Earnings
Sep 30, 2016
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did PXRB perform over the long term?
See historical performance and comparison